
https://www.science.org/content/blog-post/these-fragments-i-have-shored-against-my-ruins
# These Fragments I Have Shored Against My Ruins (January 2008)

## 1. SUMMARY

The article describes the emerging trend of fragment-based drug discovery (FBDD) in the biotechnology industry around 2008. The author explains that FBDD involves screening much smaller molecules (half the usual molecular weight or less) than traditional drug discovery, typically finding compounds with weaker binding affinities in the micromolar range rather than the nanomolar range desired for clinical candidates.

Key challenges identified include: difficulty detecting weak binders with standard assays, solubility issues when running high compound concentrations, the need for structural information (NMR or X-ray crystallography) to guide optimization, the difficulty of linking two fragments together effectively, and the problem that individual fragments may bind differently than how they behave when integrated into the complete molecule. The author notes that fragment approaches will likely miss some drug targets but supports exploring the methodology alongside traditional methods.

## 2. HISTORY

Fragment-based drug discovery has proven to be a successful and widely adopted approach in pharmaceutical research since 2008. Several drugs discovered using FBDD have reached FDA approval, most notably **Vemurafenib** (Zelboraf), approved in 2011 for treating BRAF V600E mutation-positive metastatic melanoma. Vemurafenib was co-developed by Roche and Plexxikon using fragment-based approaches.

Other notable successes include **Venetoclax** (Venclexta), an FDA-approved BCL-2 inhibitor for certain leukemias developed using fragment screening by Abbott/AbbVie and Genentech. Additionally, **Erdafitinib** (Balversa) was approved in 2019 for bladder cancer treatment, originating from fragment-based screening.

The methodology has become standard practice across the pharmaceutical industry. Major companies including Novartis, AstraZeneca, GSK, Pfizer, and numerous biotech firms have established fragment-based discovery platforms. Academic research centers have also widely adopted these techniques.

The technical challenges described in the 2008 article have been largely addressed through improved biophysical methods, better fragment libraries, advanced X-ray crystallography capabilities, and refined computational approaches for fragment linking and optimization.

## 3. PREDICTIONS

**Author's stance on fragment-based drug discovery:**
- **Prediction**: The author expressed that FBDD approaches "are probably always going to miss things" but also noted "we miss plenty of things with the traditional methods, too"
- **Outcome**: This balanced assessment proved accurate. FBDD has succeeded in identifying multiple FDA-approved drugs and become a mainstream approach, but it hasn't completely replaced traditional high-throughput screening methods, which continue to produce drugs as well.

**Implicit predictions about technical challenges:**
- **Challenge**: Finding suitable pairs of compounds for linking and successfully connecting them
- **Outcome**: Fragment linking has remained challenging, but the field has developed more sophisticated computational and experimental approaches. More commonly, FBDD practice has focused on fragment growing/optimization, as the author anticipated.

**Author's skepticism about methodology limitations:**
- **Concern**: Emergent/context-dependent binding modes where fragments behave differently when isolated versus in complete molecules
- **Outcome**: This phenomenon remains a real limitation of FBDD, but hasn't prevented the approach from achieving substantial success. The field has developed better ways to identify and work around such cases.

## 4. INTEREST

Rating: **7/10**

The article captured an important methodological shift in drug discovery at its critical growth phase and provided appropriately nuanced skepticism. Several drugs discovered through fragment-based approaches subsequently achieved FDA approval and widespread clinical use, validating the approach while confirming some technical limitations foreseen by the author.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20080122-these-fragments-i-have-shored-against-my-ruins.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_